CLINICAL TRIALS PROFILE FOR MAXIPIME
✉ Email this page to a colleague
All Clinical Trials for Maxipime
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Clinica Palermo, Bogota | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Fundación San Carlos, Bogota | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Hospital san Jorge, Pereira | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
NCT00609375 ↗ | Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen | Completed | Hospital san Juan de Dios, Antioquia | Phase 4 | 2006-09-01 | To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Maxipime
Condition Name
Clinical Trial Locations for Maxipime
Trials by Country
Clinical Trial Progress for Maxipime
Clinical Trial Phase
Clinical Trial Sponsors for Maxipime
Sponsor Name
Sponsor Name for Maxipime | |
Sponsor | Trials |
Hospital san Jorge, Pereira | 1 |
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 1 |
Hospital san Juan de Dios, Antioquia | 1 |
[disabled in preview] | 2 |
This preview shows a limited data set Subscribe for full access, or try a Trial |